$PHAR

Pharming Group N.V. (PHARM) reported positive Phase II data for leniolisib in PIDs, showing improvements in spleen volume and lung function. The drug was well-tolerated, and all participants continued treatment. Topline CVID Phase II data is expected in November, potentially expanding the drug's market.

Juan Andres will return from retirement to serve as COO of Moderna, effective October 5. Meanwhile, Pharming's CEO has departed following disagreements with the board. Neurocrine has also announced a leadership change.

Pharming Group shares fell up to 6.5% after CEO Fabrice Chouraqui resigned due to a strategic disagreement with the board. The stock later recovered to a 1.63% loss, trading at €0.905. Interim co-CEOs Leverne Marsh and Kenneth Lynard were appointed, with the board beginning a search for a permanent replacement. The company's strategy and pipeline remain unchanged.

Pharming Group NV announced that Fabrice Chouraqui will step down as CEO and Executive Director effective immediately. The company has not yet named a successor.

Pharming Group (PHAR) announced FDA acceptance of its sNDA for lower doses of Joenja in children aged 4+ with APDS, granted Priority Review with a PDUFA target date of Jan 30, 2027. The application is supported by positive Phase 3 study data. Joenja is currently approved for adults and pediatric patients aged 12+ with APDS. PHAR stock is up 0.27% at $10.47.

First Berlin Equity Research maintained a Buy rating on Pharming Group NV but reduced its price target to €2.20 from €2.40, citing weaker-than-expected Q2 results. The company's Q2 performance was below expectations, according to the analyst.

The FDA approved Pharming's Joenja for treating children aged 4-11 with APDS, a rare immunodeficiency. The Dutch biopharma firm (PHARM) expects the new pediatric doses to be available in the US in October. This marks the first FDA-approved treatment for this age group with APDS.

Pharming Group (PHAR) said Joenja (leniolisib) has started commercial sales in Japan for APDS patients aged 4 and older, after inclusion on Japan’s NHI price list. The drug is an oral PI3K delta inhibitor approved based on a Phase III trial and supported by long-term extension data. OrphanPacific is the local partner.

Pharming Group N.V. (PHAR) furnished an SEC Form 6-K — earnings release. Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., dated July 30, 2026. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja mom

Pharming Group cut its 2026 revenue guidance by $30 million to $375 million to $395 million, citing weaker Q2 sales and continued weakness in its legacy Ruconest product. Q2 revenue was $90.2 million versus $100.8 million consensus. Ruconest sales fell 10% to $72.3 million, below $83.8 million. Operating profit was $1.3 million.